

COUNTRY GENERAL INFORMATION (WHO, 2015)

Total population:	18,502,000
Gender F / M (%):	49.1 / 50.9
Population, age group <15/≥15 years (%):	35 / 65
Life expectancy at birth (F/M, years) (2015):	70 / 60
GDP (PPP int \$):	Not available
Income status:	Lower middle
Number of 1 st sub-national administrative level divisions, name:	14, Governorate

EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	20	39,800	11,172	N/A
Number of relapses ¹ :	No data	No data	No data	N/A
Total number of cases:	20	39,800	11,172	N/A
Imported cases (#, %):	No data	No data	No data	No data
Gender distribution (% F):	30%	48%	48%	N/A
Age group distribution (% < 5/5-14/>14):	(55/25/20)	(21/31/48)	(24/26/50)	N/A
Incidence rate (cases/10,000 population in endemic areas):	0.02	18.86	13.90	N/A
Number of endemic 1 st sub-national administrative level divisions:	6	12	5	N/A
Population at risk ² (% # at risk/total population):	68% 12,530,000/18,502,000	100% 18,502,000/18,502,000	43% 8,036,000/18,502,000	N/A
Was there any outbreak?	No data	No data	No data	N/A
Number of new ³ foci:	1	No data	No data	N/A


N/A = Not applicable; ¹ Relapse in this country is defined as: No definition available; ² Defined as "Number of people living in 1st sub-national administrative level endemic areas"; ³ Defined as "In this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever".

Monthly distribution of new cases (January-December)


2015	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	0	1	1	2	4	1	0	2	3	2	2	2
ACL	4,669	3,535	3,837	3,073	2,629	2,135	1,657	1,797	1,734	2,313	7,439	4,987
ZCL	2,104	1,838	1,308	677	405	170	85	143	189	430	1,618	2,205

VL = visceral leishmaniasis; ACL = Anthroponotic cutaneous leishmaniasis; ZCL = Zoological cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

Visceral leishmaniasis




Cutaneous leishmaniasis




Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015

Visceral leishmaniasis




Cutaneous leishmaniasis



Disease distribution of new VL and CL cases at governorate level per 10,000 population (2015)

Visceral leishmaniasis





www.who.int/leishmaniasis/Map-VL-Syria-2015.png

The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Map production: WHO/HTM/NTD/IDM

Cutaneous leishmaniasis



CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:

Type of surveillance:

Is there a vector control programme?

Type of insecticide used for Indoor residual Spraying (IRS):

Year latest national guidelines:

Is leishmaniasis notifiable (mandatory report)?

Is there a reservoir host control programme?

Number of leishmaniasis health facilities:

Not available

Integrated

Yes

Pyrethroids, WP & SC

2010

Yes

Yes

220

DIAGNOSIS

Number of people screened actively for:

Number of people screened passively for:

VL cases diagnosed by RDT* (% , # RDT+ / total VL cases):

Proportion of positive RDT* (% , # RDT+ / total RDT):

Cases diagnosed by direct exam* (parasitology) (% , # slides + / total cases):

Proportion of positive slides* (% , # slides + / total slides):

Cases diagnosed clinically* (% , # clinical cases / total cases):

Proportion of CL cases with lesions equal to or greater than 4 cm*:

Proportion of CL cases with 4 or more lesions* (% , # CL cases / total CL cases):

Percentage of cases with HIV coinfection*:

VL = visceral leishmaniasis; ACL = Anthroponotic cutaneous leishmaniasis; ZCL= Zoological cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis
N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

▶ Is treatment provided for free in the public sector? Yes

▶ Antileishmanial medicines included in the National Medicine List: Sodium stibogluconate (SSG), Meglumine antimoniate, cryotherapy

TREATMENT OUTCOME

Proportion of cases treated (% , # treated cases / total cases):

Initial cure rate(% , # cases initially cured / total cases):

Failure rate⁴ (% , # patients with treatment failure / total cases):

Case fatality rate (% , # patients who died / total cases):

	VL	ACL	ZCL	MCL
Number of people screened actively for:	No data	No data	No data	N/A
Number of people screened passively for:	No data	No data	No data	N/A
VL cases diagnosed by RDT* (% , # RDT+ / total VL cases):	50% (10/20)	N/A	N/A	N/A
Proportion of positive RDT* (% , # RDT+ / total RDT):	91% (10/11)	N/A	N/A	N/A
Cases diagnosed by direct exam* (parasitology) (% , # slides + / total cases):	90% (18/20)	No data	No data	N/A
Proportion of positive slides* (% , # slides + / total slides):	89% (16/18)	No data	No data	N/A
Cases diagnosed clinically* (% , # clinical cases / total cases):	No data	No data	No data	N/A
Proportion of CL cases with lesions equal to or greater than 4 cm*:	N/A	No data	No data	N/A
Proportion of CL cases with 4 or more lesions* (% , # CL cases / total CL cases):	N/A	No data	No data	N/A
Percentage of cases with HIV coinfection*:	No data	N/A	N/A	N/A

VL = visceral leishmaniasis; ACL = Anthroponotic cutaneous leishmaniasis; ZCL= Zoological cutaneous leishmaniasis

⁴ Failure in this country is defined as: No definition available

* These indicators only apply for new cases